KD Logo

Viridian Therapeutics Inc (VRDN) receives an Outperform rating from Credit Suisse

Viridian Therapeutics Inc’s filing revealed that its Director Fairmount Funds Management LLC acquired Company’s shares for reported $10.0 million on Jan 22 ’24. In the deal valued at $21.00 per share,476,190 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 1,839,954 shares worth roughly $25.02 million.

Then, Meisner Lara sold 27 shares, generating $765 in total proceeds. Upon selling the shares at $28.35, the Chief Legal Officer now owns 29,971 shares.

Before that, Meisner Lara sold 2,269 shares. Viridian Therapeutics Inc shares valued at $63,577 were divested by the Chief Legal Officer at a price of $28.02 per share. As a result of the transaction, Meisner Lara now holds 29,971 shares, worth roughly $0.41 million.

A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid June with a ‘”a Buy”‘ rating. RBC Capital Mkts began covering VRDN with “an Outperform” recommendation on May 30, 2023. Wells Fargo started covering the stock on April 17, 2023. It rated VRDN as “an Overweight”.

Price Performance Review of VRDN

On Monday, Viridian Therapeutics Inc [NASDAQ:VRDN] saw its stock jump 5.59% to $13.60. Over the last five days, the stock has lost -4.90%. Viridian Therapeutics Inc shares have fallen nearly -37.56% since the year began. Nevertheless, the stocks have fallen -50.99% over the past one year. While a 52-week high of $28.99 was reached on 01/09/24, a 52-week low of $10.93 was recorded on 04/25/24. SMA at 50 days reached $17.10, while 200 days put it at $17.59. A total of 1.07 million shares were traded, compared to the trading of 0.77 million shares in the previous session.

Levels Of Support And Resistance For VRDN Stock

The 24-hour chart illustrates a support level at 12.91, which if violated will result in even more drops to 12.22. On the upside, there is a resistance level at 13.96. A further resistance level may holdings at 14.32. The Relative Strength Index (RSI) on the 14-day chart is 32.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.21%. Stochastics %K at 18.60% indicates the stock is a buying.

The most recent change occurred on March 30, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $49 price target.

Most Popular

[the_ad id="945"]